N Engl J Med 2017 Nov 16
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Abstract
Background
Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy.
Methods
We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety.
Results
Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events.
Conclusions
Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).
Related Questions
How long would you hold cemiplimab before and after thoracic chemoradiation?
Cemiplimab is certainly not the accepted standard ICI to be used after chemoradiation in stage III NSCLC, although it is being tested in the SPORADIC trial as part of induction chemo-ICI and consolidation ICI with radiotherapy alone in patients unfit for chemoradiation. It is not advised to give con...
How would you approach a locally advanced NSCLC s/p pneumonectomy now with multi-station mediastinal nodal recurrence?
Very tough clinical scenario. I routinely say that in an era where we have good options with both peri-op chemoimmunotherapy or chemoradiation followed by immunotherapy, patients with LA-NSCLC shouldn't be getting pneumonectomies (with rare exceptions). Stepping off that soapbox, I'd start with a go...
Is there a role for the addition of radiation to preoperative chemoimmunotherapy in NSCLC with limited N2 disease planned for surgery?
CheckMate 816 was a phase III randomized trial that demonstrated that adding nivolumab to platinum-based chemotherapy in the neoadjuvant setting improved pCR rates and event-free survival (Forde et al., PMID 35403841) and ultimately overall survival (NEJM 2025). The 5-year OS benefit was 10%, almost...
Is concurrent immuno-radiation therapy a viable treatment option for patients with unresectable, non-metastatic, locally advanced lung cancer, who have high PD-L1 expression and no oncogenic mutations?
Concurrent radiation and immunotherapy would not be recommended for patients with unresectable locally advanced NSCLC.The standard of care in this scenario is concurrent chemotherapy and radiation followed by consolidation durvalumab based on survival improvements seen with the addition of durvaluma...
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
The long recruitment period and change in the practice of brachytherapy do create some uncertainty in interpretation. As mentioned, 60% had point A-based brachytherapy in INTERLACE. Any modern cervical cancer trial needs to have current technology especially IMRT (helps with nodal boost, conformity,...
What, if any, resources exist with recommendations regarding the timing and toxicity of radiation in patients who have received or are currently on immunotherapy?
Concurrent immunotherapy (PD1/PDL1) with chemoradiation is now not advised, given the two negative lung cancer trials (PACIFIC 2, CheckMate 73L). Concurrent immunotherapy with radiation alone is still an interesting area to explore, as the two published studies (SPRINT, Ohri et al., PMID 37988638, a...
How do you treat Stage IIIC T4N3 NSCLC?
Probably need a bit more information since T4 is fairly heterogeneous, but it is absolutely treatable. If it involves both ipsilateral lobes, then SBRT to one isolated lesion and CRT for the rest is one approach. If T4 is involved in critical mediastinal organs, probably some induction therapy with ...
How do you decide between neoadjuvant or perioperative chemoimmunotherapy, as per Checkmate 816 or KEYNOTE-671, for early-stage NSCLC?
All of us caring for patients with a lung cancer diagnosis face a very challenging “now what” scenario following publications of many studies demonstrating benefits of a neoadjuvant and/or perioperative approach for the treatment of patients with resectable NSCLC with already 2 FDA approvals of the ...
What are your top takeaways in Thoracic Cancers from ASCO 2023?
Always so hard to pick a top 3 as luckily each ASCO provides us with a broad spectrum of significant advances in our field but if pressed against the wall, I might pick below 3: The first is a double dip choice I admit matching ADAURA with KN789. Of course, you need to be living in a cave not to be ...
How do you manage stage III resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy per CheckMate 816 with residual disease who subsequently refuse surgery?
(1) Carefully analyze what happened with the patient, their medical oncologist, and thoracic surgeon, (2) restage the patient with an FDG-PET/CT and brain MRI to rule out distant metastatic progression, (3) confirm with their medical oncologist that CRT-> Durva is still an option, (4) confirm that a...
Do you consider NSCLC with multistation N2 involvement appropriate for treatment with neoadjuvant chemoimmunotherapy followed by surgery?
Interesting question and something that is frequently discussed in tumor boards. Multistation N2 patients were not included in neoadjuvant trials and hence, any adaptation of this strategy to patients with advanced N staging would not be appropriate at this time. Further, given level 1 evidence from...
Would you offer RT for a nodal recurrence of NSCLC that has resolved radiographically after chemotherapy?
Nodal recurrences are bad. When addressing nodal disease that "disappears" after chemotherapy, I have modeled my decision making on the premise used in small cell lung cancer treatment where even in the face of CRs on imaging after chemotherapy, radiotherapy was always added to the mediastinal (noda...
Are there any situations where you would consider neoadjuvant chemoradiation as opposed to chemoimmunotherapy for patients with resectable NSCLC prior to surgical resection?
For most of the last 2 decades, there has been a raging debate about the best perioperative approach for the management of patients with high-risk resectable NSCLC, such as patients for example, with preop documented nodal disease. Clinical studies have not been able to settle the key questions whet...
How do you choose between neoadjuvant and adjuvant chemo-immunotherapy for patients with resectable stage II-IIIA NSCLC?
The billion dollar question. For patients with resectable stage II-IIIA NSCLC, how do you choose between neoadjuvant and adjuvant chemo-immunotherapy in light of the recent FDA approval of the CheckMate-816 regimen? Of course, this approval quickly followed in the footsteps of the FDA approval of at...
Would you consider SBRT and adjuvant therapy for a 4cm, node-negative, non-oncogene driven, NSCLC not amenable to surgical resection?
Ultimately, currently open clinical trials will address this question (i.e., SWOG-S1914, NCT04214262). In the absence of this, there have been several questions here on this topic ranging from the possible role for adjuvant chemotherapy, incorporating ctDNA testing, and how to follow these patients ...
Do you offer consolidation durvalumab in stage III patients with NSCLC who developed grade 2 radiation pneumonitis during chemoradiation?
The cleanest answer is no, I would not put a patient on durvalumab who experienced pneumonitis during radiation. This is in keeping with the clinical protocol for the PACIFIC trial which excluded patients who experienced any grade pneumonitis during radiation (including grade 1). The reason we now o...
For which patients with resected NSCLC will you offer adjuvant atezolizumab after completion of cisplatin-based adjuvant chemotherapy?
The initial results of IMpower010 were presented by Dr. @Dr. First Last at ASCO 2021. This study demonstrated that adjuvant atezolizumab following surgical resection and adjuvant platinum based chemotherapy improved disease free survival in stage II-IIIA NSCLC patients with tumors with PDL1 expressi...
How do you approach missed doses of durvalumab consolidation in patients with Stage III NSCLC?
This is a common topic that comes up in clinic. In a previous question, the discussion centered around when/if to resume durvalumab if treatment was held due to toxicity. Here, I assume missed doses occurred for non-irAE reasons. Personally, I discontinue treatment at the completion of 1 year of the...
Would you continue durvalumab beyond 12 months in an oligometastatic NSCLC patient treated with concurrent CRT followed by consolidation durvalumab after treating a single metastatic site?
There are really a few questions here. The first is duration of durvalumab, and I agree with prior answer by @Dr. First Last that stopping at 1 year is appropriate given that was specified in PACIFIC (though only 42% of patients actually completed 1 yr of durvalumab in the study). Then there is the ...
How do you approach patients with stage III unresectable, combined histology NSCLC/SCLC?
For stage III lung cancer with mixed NSCLC and small-cell lung cancer, we treat patients with concurrent chemotherapy (cisplatin/etoposide every three weeks) and definitive radiotherapy (60-66 Gy in 30 fractions, QD), followed by adjuvant immunotherapy (durvalumab). The rationales are as follows: Ra...